Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH)

Saskia Antwerpes,Vincent Di Beo,Fabienne Marcellin,Philippe Morlat,Camelia Protopopescu,Philippe Sogni,The Anrs Co13 Hepavih Study Group ,Laurent Michel,Dominique Salmon-Céron,Linda Wittkop,Maria Carrieri

doi:10.3390/nu12092532

Abstract

Coffee is one of the most consumed beverages worldwide. Previous research has demonstrated its neuroprotective effects in the elderly. People coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) experience an accelerated aging process and cognitive impairment, which significantly impair quality of life and may affect disease-related dimensions such as treatment adherence. This study aimed to analyse the relationship between regular coffee intake and neurocognitive performance (NCP) in HIV-HCV coinfected people. We used data from 139 coinfected patients who participated in both the ANRS CO13 HEPAVIH cohort and the HEPAVIH-Psy cross-sectional survey. Linear regression models adjusting for potential sociodemographic (age, gender, educational level), clinical (liver disease status, ongoing HCV treatment, HIV viral load, major depressive disorder) and socio-behavioural (cannabis use) correlates of NCP were used. Our results showed significant, positive associations between elevated coffee intake (ECI) (three or more cups of coffee per day) and NCP in verbal fluency, psychomotor speed (coding) and executive functioning. ECI might therefore preserve neurocognitive functioning in people living with HIV and HCV.

Highlights

Coffee is one of the most widely consumed drinks in the world, especially in high-resource settings [1]
We used data from 139 human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfected patients who participated in both the ANRS CO13
This is the first study to explore the relationship between coffee intake and neurocognitive performance in people coinfected with HIV and HCV

Summary

Introduction

Coffee is one of the most widely consumed drinks in the world, especially in high-resource settings [1]. It is associated with better overall health and a reduced risk of both mortality [2] and cancer [3] in the general population. In people living with HIV and HCV, previous research has shown that ECI can reduce the risk of mortality by 50% [8]. With regard to liver function, Yaya et al pointed out that ECI is associated with a significantly reduced risk of advanced liver fibrosis in HIV-HCV coinfected patients, even in those with unhealthy alcohol use [9]. Other beneficial effects of ECI in this population are its positive effects on insulin resistance [10], perceived toxicity and fatigue [11]

Objectives

Methods

Discussion

Conclusion